Idera Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
August 30 2018 - 7:30AM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical
company focused on the development and commercialization of its
proprietary immune modulator, tilsotolimod, for the treatment of
cancer, today announced that the company will participate in the
H.C. Wainwright 20th Annual Global Investment Conference on
Wednesday, September 5, 2018 at 2:10 p.m. Eastern Time at the St.
Regis Hotel in New York City.
Live audio webcast of Idera’s presentations will be accessible
in the Investors and Media section of Idera’s website at
http://www.iderapharma.com. Archived versions will also be
available on the Company’s website after the event for 90
days.
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and Idera’s
experience in developing proprietary immunology technologies,
Idera’s lead development program is focused on priming the immune
system to play a more powerful role in fighting cancer, ultimately
increasing the number of people who can benefit from immunotherapy.
Idera is committed to working with investigators and partners who
share the common goal of addressing the unmet needs of patients
suffering from difficult to treat, unmet cancers. To learn more
about Idera, visit www.iderapharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including statements
regarding the Company’s strategy, future operations,
collaborations, cash resources, financial position, future
revenues, projected costs, prospects, clinical trials, plans and
objectives of management, are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “continue,” “will,” and “would” and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company’s
forward-looking statements. There are a number of important factors
that could cause Idera’s actual results to differ materially from
those indicated or implied by its forward-looking statements,
including whether the Company’s cash resources will be sufficient
to fund the Company’s continuing operations and the further
development of the Company’s programs for the period anticipated;
whether interim results from a clinical trial will be predictive of
the final results of the trial; whether results obtained in
preclinical studies and clinical trials will be indicative of the
results that will be generated in future clinical trials; whether
products based on the Company’s technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors set forth under the
caption “Risk Factors” in the Company’s Annual Report on Form 10-K
for the period ended December 31, 2017 and in the Company’s
Quarterly Report on Form 10-Q for the period ended June 30, 2018.
Although Idera may elect to do so at some point in the future, the
Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Investor and Media ContactRobert DoodyVice
President, Investor Relations and Corporate CommunicationsOffice:
617-679-5515Mobile: 484‐639‐7235rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2024 to Jun 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Jun 2023 to Jun 2024